Published in Vaccine Weekly, July 28th, 2004
The company also updated the status of a parallel phase II trial in patients with operable pancreatic cancer who receive the vaccine after surgery, an approach which continues to be the focus of the company's GVAX pancreatic cancer vaccine program. These 2 trials were prompted by encouraging results from an earlier phase I clinical trial in operable patients which demonstrated prolonged, disease-free survival of at least 6 years in 3 of 8 patients treated at therapeutic dose...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly